Before We Start
Different steps, one combined regimen
HIV mutates fast enough that a single drug, however effective at first, will eventually be defeated. Combining drugs that hit completely different steps of replication means the virus would need multiple, simultaneous, unrelated mutations to escape treatment entirely.
💡 Memory Trick
ART: NRTIs + NNRTIs (reverse transcriptase) · PIs (protease) · INSTIs (integrase) · Fusion inhibitors. Four genuinely different steps blocked at once is what makes combination therapy so hard for the virus to outrun.
The Key Points
Four drug classes, each targeting a different life-cycle step
NRTI
Nucleoside RT inhibitors — chain terminators
NRTIs (tenofovir, emtricitabine, abacavir) work as chain terminators — they lack the 3'-OH group needed to continue building the viral DNA chain, so once incorporated, reverse transcription simply stops.
🦠 Once an NRTI molecule gets incorporated into the growing viral DNA chain, the chain simply cannot extend any further — the missing 3'-OH group makes further addition chemically impossible.
NNRTI
Non-nucleoside RT inhibitors — a different binding approach entirely
NNRTIs (efavirenz, nevirapine) also target reverse transcriptase, but bind it allosterically (at a separate site) rather than being incorporated into the DNA chain itself.
🦠 An NNRTI doesn't need to be incorporated into the DNA chain at all — it distorts the reverse transcriptase enzyme's shape from a separate binding site, disabling it through a mechanistically distinct route from NRTIs.
PI
Protease inhibitors — blocking viral maturation
Protease inhibitors (ritonavir, atazanavir) block the cleavage of viral polyproteins into their functional pieces, resulting in immature, non-infectious virions.
🦠 New viral particles are still assembled and released even with a protease inhibitor on board — they simply come out immature and non-infectious, unable to go on to infect a new cell.
INSTI
Integrase inhibitors — the preferred first-line class
Integrase strand transfer inhibitors (dolutegravir, raltegravir) block the viral DNA from integrating into the host cell's genome. Dolutegravir in particular is currently a preferred first-line agent. Standard treatment combines drugs from multiple classes into a three-drug regimen (ART/HAART) specifically to prevent resistance.
🦠 A newly diagnosed HIV patient is started on a three-drug regimen combining an integrase inhibitor with two NRTIs — a standard first-line approach that hits HIV replication at multiple distinct steps simultaneously, making it much harder for the virus to develop resistance to the entire regimen at once.
🏥 Applied Scenario
A patient newly diagnosed with HIV is started on treatment, and the regimen includes dolutegravir alongside two other drugs from a different class.
Step 1
Ask why a single drug wouldn't be used instead: Why not just use a single, highly effective drug rather than combining three? Because HIV mutates extremely rapidly, and a single drug — no matter how effective initially — will eventually select for resistant viral mutants if used alone.
Step 2
Explain why combining different classes specifically works: Combining drugs that target different steps of the replication cycle (here, an integrase inhibitor plus two chain-terminating NRTIs) means the virus would need to simultaneously develop resistance mutations against multiple, mechanistically unrelated drugs at once — a far less likely event than developing resistance to just one.
Step 3
Recognize the standing standard of care: This is exactly why standard HIV treatment (ART/HAART) is built around combination therapy from the start, rather than being escalated to combination therapy only after a single drug fails, the way antibiotic therapy sometimes is for other infections.
Step 4
Conclusion: Combination therapy for HIV isn't a fallback for treatment failure — it's the standard, preventive strategy from day one, precisely because of how fast the virus can otherwise develop resistance.
📌 Exam Application
Exams test matching each of the four drug classes (NRTI, NNRTI, PI, INSTI) to its specific point of action in HIV's replication cycle, understanding NRTIs' chain-termination mechanism specifically (no 3'-OH group), and why standard treatment always uses a multi-drug combination regimen rather than single-drug therapy.
⚠️ The Trap — Confusing NRTIs and NNRTIs
The most common trap is confusing NRTIs and NNRTIs, since both target reverse transcriptase but through completely different mechanisms — NRTIs are incorporated directly into the growing DNA chain and terminate it, while NNRTIs bind allosterically at a separate site without being incorporated at all. The shared target (reverse transcriptase) makes it easy to assume a shared mechanism, but the two work in genuinely different ways.
✓ Quick Self-Test
Answer before checking:
1. How do NRTIs stop HIV replication?
2. How do NNRTIs differ mechanistically from NRTIs, even though both target reverse transcriptase?
3. What do protease inhibitors block, and what's the result?
4. What do integrase strand transfer inhibitors block, and which drug in this class is a preferred first-line agent?
5. Why is HIV treatment always given as a multi-drug combination rather than a single drug?
Answers:
1. They act as chain terminators — lacking a 3'-OH group, they stop viral DNA chain elongation once incorporated during reverse transcription.
2. NNRTIs bind reverse transcriptase allosterically at a separate site, rather than being incorporated into the DNA chain the way NRTIs are.
3. They block cleavage of viral polyproteins into functional pieces, resulting in immature, non-infectious virions.
4. They block viral DNA from integrating into the host genome; dolutegravir is a preferred first-line agent.
5. Because HIV mutates rapidly, and single-drug therapy would quickly select for resistant mutants; combining drugs targeting different replication steps makes simultaneous resistance to the entire regimen far less likely.